Editas medicine stock price.

Nov 24, 2023 · Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19. The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Deardorf’s ...Moreover, the 36-month beta value for EDIT is 1.79. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 8 as “hold,” and 1 as “sell.” The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $5.41 above the current market price.Find the latest Editas Medicine, Inc. (8EM.F) stock quote, history, news and other vital information to help you with your stock trading and investing.The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD.

Editas Medicine is a high-risk stock with the potential of a big reward. ... Current Price. $10.88. Price as of November 29, 2023, 11:23 a.m. ET.

Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...

Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 8.55% so far this month. During the month of April, Editas Medicine Inc’s stock price has reached a high of $7.21 and a low of $6.45. Over the last year, Editas Medicine Inc has hit prices as high as $20.04 and as low as $6.70. Year to date, Editas ...Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).Nov 21, 2023 · Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $). Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ...Recent reports have lowered Editas Medicine’s price target from $36.00 to $30.00 and raised it from $13.00 to $15.00. Editas Medicine’s stock opened at $6.71 and has a 50-day moving average of $8.70 and a 200-day moving average of $9.86. The company’s market capitalization is $462.79 million, and it has a PE ratio of -2.09 and a …

Editas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.

What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...

See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Find the latest Editas Medicine, Inc. (EDIT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

May-11-23 10:32AM. Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress. (GlobeNewswire) May-10-23 06:02AM. Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%. (Simply Wall St.)Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsEditas Medicine stock price prediction is an act of determining the future value of Editas Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Editas Medicine's future price could yield a significant profit.Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences.Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …

Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Nov 20, 2023 · The average price target on the stock implies a 67% gain over the next 12 months. ... The past month has been a great one for Editas Medicine (EDIT 0.86%), but the stock is still down about 89% ... Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Editas Medicine Inc’s Stock Price as of Market Close. As of May 16, 2023, 4:00 PM CST, Editas Medicine Inc’s stock price was $9.55. Editas Medicine Inc is down 4.6% from its previous closing price of $10.01. During the last market session, Editas Medicine Inc’s stock traded between $9.58 and $10.51. Currently, there are 68.92 …Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $).Editas Medicine (NASDAQ: EDIT) has extended post-market gains to rise ~9% in early trading on Tuesday after the company announced a favorable decision issued by U.S. patent officials backing the ...Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksCAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ...

Different countries and cultures worldwide have used medicinal plants for thousands of years. Several studies have looked into the usefulness of these medicinal plants. However, more research is still ongoing to understand the medical benef...

Editas Medicine Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time EDIT stock price.

Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …With Editas Medicine stock trading at $10.49 per share, the total value of Editas Medicine stock (market capitalization) is $856.76M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... Snap's stock is now far below its all-time high of close to $80 in 2021, but patient investors could see shares reach and exceed that price. Prosper Junior Bakiny has no position in any of the ...Mar 30, 2023 · Editas Medicine is a high-risk stock with the potential of a big reward. ... Current Price. $10.88. Price as of November 29, 2023, 11:23 a.m. ET. Dec 1, 2023 · With Editas Medicine stock trading at $6.26 per share, the total value of Editas Medicine stock (market capitalization) is $511.02M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016. The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as ...Why Editas Medicine Stock Charged Higher in January. By George Budwell – Feb 2, 2023 at 11:33AM Key Points. ... Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET.Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... Editas Medicine (EDIT 2.28%) is on the cutting edge of CRISPR. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR ...On June 15, Editas Medicine ( EDIT 3.66%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ...

Why Editas Medicine Stock Charged Higher in January. By George Budwell – Feb 2, 2023 at 11:33AM Key Points. ... Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET.12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...The sale of Editas stock could be related to the biotech's upcoming announcement of clinical data. ... Price as of November 29, 2023, 4:00 p.m. ET ... Keith Speights owns shares of Editas Medicine ...Instagram:https://instagram. reliance steel and aluminum co.owner of vivintohio fha mortgagewinery stocks The decrease was driven by reduced headcount related expense, including stock compensation, and reduced legal costs. Upcoming Events Editas Medicine plans to participate in the following scientific and medical conference: American Society of Hematology (ASH) ... Chardan Cuts Price Target on Editas Medicine to $19 From $22, … acgyxhome mortgages for small business owners In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00. duke enwrgy Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsDec 1, 2023 · 12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...